Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Pietrantonio, Filippo; Salvatore, Lisa; Esaki, Taito; Modest, Dominik Paul; Lopez-Bravo, David Paez; Taieb, Julien; Karamouzis, Michalis V.; Ruiz-Garcia, Erika; Kim, Tae Won; Kuboki, Yasutoshi; Meriggi, Fausto; Cunningham, David; Yeh, Kun-Huei; Chan, Emily; Chao, Joseph; Tran, Qui; Cremolini, Chiara; Fakih, Marwan

doi:10.1200/jco-24-02026

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty…